Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
August 06, 2024 07:30 ET
|
Anavex Life Sciences Corp.
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
August 01, 2024 07:30 ET
|
Anavex Life Sciences Corp.
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
July 30, 2024 07:30 ET
|
Anavex Life Sciences Corp.
ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS) Therapeutic potential to address behavioral and cognitive deficits in individuals with...
Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
July 28, 2024 17:00 ET
|
Anavex Life Sciences Corp.
Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events Clinical...
Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 20, 2024 07:30 ET
|
Anavex Life Sciences Corp.
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Announces Expansion of Leadership Team
May 22, 2024 07:30 ET
|
Anavex Life Sciences Corp.
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
May 14, 2024 07:30 ET
|
Anavex Life Sciences Corp.
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
May 09, 2024 07:30 ET
|
Anavex Life Sciences Corp.
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
May 02, 2024 07:30 ET
|
Anavex Life Sciences Corp.
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
April 11, 2024 07:30 ET
|
Anavex Life Sciences Corp.
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...